Latest News & Insights
Stay Up to Date with Our Community
Featured
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1...
Company announces $30 million Series A financing and founding leadership team...
Veteran biopharma leader joins to help lead Kyverna’s next phase of...
REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated...
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial...
Provides corporate update including appointment of gene therapy expert Romuald Corbau,...
Phase 1 study builds on early signals of anti-tumor activity in...
Ms. Dac brings more than 30 years of experience successfully executing...
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed...